Seres swings to Q2 profit on VOWST gain, extends cash runway to Q1 2027, and advances SER-155 in irEC
MCRB sits 21% above its 52-week low of $4.59.
Summary
Seres Therapeutics posted a $4.6M Q2 profit driven by a $25M Nestlé milestone payment, extended its cash runway to Q1 2027, and reported positive SER-155 data in irEC, while continuing to seek partnerships and capital.
Key Events · Earnings and Guidance · MCRB
-
Q2 Profit on VOWST Milestone Buyout
Net income reached $4.6M, a sharp reversal from the $19.9M loss a year ago, entirely due to a $25M gain from Nestlé buying out future VOWST milestones. Without this one-time item, the operating loss was $21.3M.
-
Cash Runway Extended to Q1 2027
Cash of $15.6M at June 30, plus $12.5M received July 1 and another $12.5M expected October 1 from Nestlé, funds operations into early 2027 — a critical extension for a company with a going-concern warning.
-
SER-155 Shows 80% Response in irEC
In an investigator-sponsored trial, 12 of 15 patients with checkpoint-inhibitor colitis achieved immunosuppressive-free clinical response at day 15. The data supports partnering discussions for this large-market indication.
-
Further Facilities Cost Reductions
An agreement to exit the 200 Sidney Street lease early eliminates remaining obligations after 2026, adding to the June restructuring of the headquarters lease — together materially lowering annual fixed costs from 2027.
Analysis · MCRB · Life Sciences
A rare profitable quarter — net income of $4.6 million — landed entirely from a $25 million milestone buyout by Nestlé. That cash, together with aggressive cost-cutting that includes an early lease exit, stretches the runway into early 2027, buying time to secure a partner or funding for lead program SER-155. The 80% response rate in checkpoint-inhibitor colitis is clinically compelling and strengthens the partnering pitch, yet the company remains in a precarious financial position with only $15.6 million in cash at quarter-end and a going-concern warning still looming. The market will weigh the improved near-term survival odds against the deep dilution risk that any financing will likely bring.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MCRB was trading at $5.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.8M. The 52-week trading range was $4.59 to $29.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.